ORKA
Oruka Therapeutics, Inc.
1W: -2.7%
1M: +20.0%
3M: +37.1%
YTD: +37.6%
1Y: +234.6%
3Y: +177.9%
5Y: +39.9%
$38.91
+0.09 (+0.23%)
After Hours: $36.48 (-2.43, -6.26%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$27.4M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.5B
52W Range5.49-42.88
Volume1,015,641
Avg Volume547,201
Beta-0.44
Dividend$19.36
Analyst Ratings
Company Info
CEOLawrence Otto Klein
Employees28
SectorHealthcare
IndustryBiotechnology
IPO Date1997-08-08
Websiteorukatx.com
221 Crescent Street Building 23, Suite 105
Menlo Park, MA
US
Menlo Park, MA
US
203-554-7604
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Latest News
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Brokerages
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down
Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect?
Company News for Mar 16, 2026
VR Adviser Adds Over 1 Million Savara Shares
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Goncalves Joana | M-Exempt | 3,500 | $6.84 | 2026-03-16 |
| Goncalves Joana | M-Exempt | 3,500 | $7.80 | 2026-03-16 |
| Goncalves Joana | S-Sale | 2,921 | $40.11 | 2026-03-16 |
| Goncalves Joana | S-Sale | 2,902 | $41.20 | 2026-03-16 |
| Goncalves Joana | S-Sale | 1,177 | $41.94 | 2026-03-16 |